

PRODUCT INFORMATION



SR 144528-d₃
Item No. 37830

Formal Name: 5-(4-chloro-3-methylphenyl)-1-(4-(methyl-d₃)benzyl)-N-((1S,2S,4R)-1,3,3-trimethylbicyclo[2.2.1]heptan-2-yl)-1H-pyrazole-3-carboxamide

MF: C₂₉H₃₁D₃ClN₃O

FW: 479.1

Chemical Purity: ≥98% (SR 144528)


Deuterium Incorporation: ≥99% deuterated forms (d₁-d₃); ≤1% d₀

UV/Vis.: λ_{max}: 201, 204 nm

Supplied as: A crystalline solid

Storage: -20°C

Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

SR 144528-d₃ is intended for use as an internal standard for the quantification of SR 144528 (Item No. 9000491) by GC- or LC-MS. The accuracy of the sample weight in this vial is between 5% over and 2% under the amount shown on the vial. If better precision is required, the deuterated standard should be quantitated against a more precisely weighed unlabeled standard by constructing a standard curve of peak intensity ratios (deuterated versus unlabeled).

SR 144528-d₃ is supplied as a crystalline solid. A stock solution may be made by dissolving the SR 144528-d₃ in the solvent of choice, which should be purged with an inert gas. SR 144528-d₃ is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide. The solubility of SR 144528-d₃ in these solvents is approximately 15, 5, and 25 mg/ml, respectively.

Description

SR 144528 is a cannabinoid 2 (CB₂) receptor antagonist (K_i = 0.6 nM).¹ It is selective for CB₂ over CB₁ receptors in CHO cells expressing the human receptors (K_i = 437 nM).² SR 144528 reverses CP 55,940-induced inhibition of forskolin-induced adenylyl cyclase activity in CHO cells expressing human CB₂ receptors (EC₅₀ = 10 nM). SR 144528 (0.01 mg/kg) reduces paw swelling in a mouse model of carrageenan-induced paw edema.³

References

1. Pertwee, R.G. Pharmacology of cannabinoid receptor ligands. *Curr. Med. Chem.* **6**(8), 635-664 (1999).
2. Rinaldi-Carmona, M., Barth, F., Millan, J., et al. SR 144528, the first potent and selective antagonist of the CB₂ cannabinoid receptor. *J. Pharmacol. Exp. Ther.* **284**(2), 644-650 (1998).
3. Iwamura, H., Suzuki, H., Ueda, Y., et al. In vitro and in vivo pharmacological characterization of JTE-907, a novel selection ligand for cannabinoid CB₂ receptor. *J. Pharmacol. Exp. Ther.* **296**(2), 420-425 (2001).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the [complete](#) Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 10/09/2025

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM